The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Novel Vaccine Formaultion To Prevent Birth Defects
Funder
National Health and Medical Research Council
Funding Amount
$530,922.00
Summary
Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in ....Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in humans.Read moreRead less
Understanding Influenza-specific T Cell Immunity In The Indigenous And Non-Indigenous Populations
Funder
National Health and Medical Research Council
Funding Amount
$49,202.00
Summary
Hospitalisation and mortality rates from influenza are high in the Indigenous population. There is an urgent need for one-shot universal vaccine that protects against seasonal and pandemic strains. To identify potential vaccine targets we firstly have to determine which viral proteins will induce a large protective immune response. These responses vary between ethnicities thus comparisons will be drawn between Indigenous and non-Indigenous Australians to determine multiple vaccine candidates tha ....Hospitalisation and mortality rates from influenza are high in the Indigenous population. There is an urgent need for one-shot universal vaccine that protects against seasonal and pandemic strains. To identify potential vaccine targets we firstly have to determine which viral proteins will induce a large protective immune response. These responses vary between ethnicities thus comparisons will be drawn between Indigenous and non-Indigenous Australians to determine multiple vaccine candidates that will be protective across ethnicities.Read moreRead less
Development Of Hepatitis B Surface Antigen As A Generic Vector For The Delivery Of Foreign CTL Epitopes.
Funder
National Health and Medical Research Council
Funding Amount
$439,642.00
Summary
Many kinds of cancer and infections display unique proteins which the body's immune system can recognise as ' foreign', and mount an immune response which, if correctly harnessed, will kill the cancer or infected cells . A way to harness the immune response is to vaccinate with these unique proteins. However, new ways need to be found to deliver the unique proteins to produce the maximal possible anti- cancer or pathogen response, and one that is long lived. In particular one needs to stimulate ....Many kinds of cancer and infections display unique proteins which the body's immune system can recognise as ' foreign', and mount an immune response which, if correctly harnessed, will kill the cancer or infected cells . A way to harness the immune response is to vaccinate with these unique proteins. However, new ways need to be found to deliver the unique proteins to produce the maximal possible anti- cancer or pathogen response, and one that is long lived. In particular one needs to stimulate the cellular arm of the immune response to produce killer cells named CTLs which specifically kill cancer or infected cells. In this project we plan to use an already-licensed human vaccine - the Hepatitis B surface antigen vaccine , or HBsAG, - and genetically modify it to contain important regions of cancer or pathogen proteins termed 'epitopes'. We surmise that immunisation with these modified HBsAg will elicit powerful CTL responses which will killer cancer or infected cells.Read moreRead less
Co-administration Of DNA Encoding Co-stimulatory Molecules Enhances The Efficacy Of Immune Response To Foreign Antigen
Funder
National Health and Medical Research Council
Funding Amount
$182,000.00
Summary
Vaccines to prevent or treat infectious diseases and some cancers are urgently needed. Infected cells and some cancer cells display unique proteins which the body's immune system can recognises as 'foreign'. The body will then mount an immune response, which, if successful, will eradicate the infected or cancerous cells. Dendritic cells (DCs) initiate the body's immune response by instructing other immune cells to mount a response. For a vaccine to be successful it is important that the vaccine ....Vaccines to prevent or treat infectious diseases and some cancers are urgently needed. Infected cells and some cancer cells display unique proteins which the body's immune system can recognises as 'foreign'. The body will then mount an immune response, which, if successful, will eradicate the infected or cancerous cells. Dendritic cells (DCs) initiate the body's immune response by instructing other immune cells to mount a response. For a vaccine to be successful it is important that the vaccine activates the DCs in the right way. We propose to activate DCs by vaccinating with DNA encoding recently identified costimulatory molecules, as well as DNA encoding the foreign antigen. Our earlier work leads us to believe that this will enhance the immune response, and lead to a more effective state of immunityRead moreRead less
HIV is one of the highest public health priorities of our time. Traditional vaccines have been unsuccessful highlighting the need for alternative approaches to HIV vaccine design. We propose to modify a novel technology developed initially for targeted drug delivery, termed “capsules”, for the purpose of inducing an immune response. This is a generic technology with applications for other infectious diseases and cancer and brings together disparate disciplines of nanochemistry and immunology.
VITAL: Vaccine Immunomodulation Throughout The Aging Lifespan
Funder
National Health and Medical Research Council
Funding Amount
$795,117.00
Summary
The elderly respond less well to vaccines than their younger counterparts. Flu is particularly dangerous to the elderly. In this proposal we will determine the likely immune mechanism undelying this difference, as well as specifically address the urgent issue of whether prior injection with a whooping cough vaccine makes Flu vaccines less likely to be effective.
Determining The Unique Processes That Control Memory B Cell-mediated Secondary Antibody Responses
Funder
National Health and Medical Research Council
Funding Amount
$853,644.00
Summary
Vaccines educate the immune system by training memory cells to make neutralizing antibodies when it re-encounters the pathogen. However, where and how these memory cells are activated in the secondary antibody response in immune animals remain unknown. Here we use cutting edge technologies to fate map and gene profile memory cells and determine the molecular switches that control the secondary antibody response. This will be complemented by human vaccine studies.
Identification And Characterisation Of HLA-E Restricted Influenza A Virus-specific CD8+ T Cells
Funder
National Health and Medical Research Council
Funding Amount
$354,156.00
Summary
With seasonal epidemics and the continual threat of a pandemic, there is an urgent need for a one-shot universal vaccine that protects against different influenza strains. This can potentially be achieved by the activation of killer T cells. I will identify new virus targets presented by a highly conserved human protein. Killer T cell recognition of these targets may provide a unique opportunity to develop an improved vaccine.
Generation Of Protective Immunity Against Severe Influenza Disease In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$1,630,970.00
Summary
Hospitalisation and death rates from influenza are high in the Indigenous population, especially when a new virus emerges. There is an urgent need for a vaccine that protects against all influenza strains. T cells recognising conserved viral regions elicit such protection. As T cells are restricted by proteins called HLAs, which vary across ethnicities, we will define T cell regions for HLAs prominent in Indigenous Australians and define how to generate protective immunity against influenza.